Standard
Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? / Andersen, Emilie S.; Lund, A.; Bagger, J. I.; Andreasen, C; Grøndahl, MF; Deacon, Carolyn F.; Hartmann, Bolette; Holst, Jens Juul; Knop, Filip Krag; Lauritsen, Tina Vilsbøll.
In:
Diabetes, Obesity and Metabolism, Vol. 20, No. 8, 08.2018, p. 1937-1943.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Andersen, ES, Lund, A, Bagger, JI, Andreasen, C, Grøndahl, MF
, Deacon, CF, Hartmann, B, Holst, JJ, Knop, FK & Lauritsen, TV 2018, '
Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?',
Diabetes, Obesity and Metabolism, vol. 20, no. 8, pp. 1937-1943.
https://doi.org/10.1111/dom.13321APA
Andersen, E. S., Lund, A., Bagger, J. I., Andreasen, C., Grøndahl, MF.
, Deacon, C. F., Hartmann, B., Holst, J. J., Knop, F. K., & Lauritsen, T. V. (2018).
Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? Diabetes, Obesity and Metabolism,
20(8), 1937-1943.
https://doi.org/10.1111/dom.13321Vancouver
Andersen ES, Lund A, Bagger JI, Andreasen C, Grøndahl MF
, Deacon CF et al.
Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? Diabetes, Obesity and Metabolism. 2018 Aug;20(8):1937-1943.
https://doi.org/10.1111/dom.13321Author
Andersen, Emilie S. ; Lund, A. ; Bagger, J. I. ; Andreasen, C ; Grøndahl, MF ; Deacon, Carolyn F. ; Hartmann, Bolette ; Holst, Jens Juul ; Knop, Filip Krag ; Lauritsen, Tina Vilsbøll. / Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. In: Diabetes, Obesity and Metabolism. 2018 ; Vol. 20, No. 8. pp. 1937-1943.
Bibtex
@article{631116d895cf4875a4685b2fbc50d8bb,
title = "Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?",
author = "Andersen, {Emilie S.} and A. Lund and Bagger, {J. I.} and C Andreasen and MF Gr{\o}ndahl and Deacon, {Carolyn F.} and Bolette Hartmann and Holst, {Jens Juul} and Knop, {Filip Krag} and Lauritsen, {Tina Vilsb{\o}ll}",
year = "2018",
month = aug,
doi = "10.1111/dom.13321",
language = "English",
volume = "20",
pages = "1937--1943",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "8",
}
RIS
TY - JOUR
T1 - Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
AU - Andersen, Emilie S.
AU - Lund, A.
AU - Bagger, J. I.
AU - Andreasen, C
AU - Grøndahl, MF
AU - Deacon, Carolyn F.
AU - Hartmann, Bolette
AU - Holst, Jens Juul
AU - Knop, Filip Krag
AU - Lauritsen, Tina Vilsbøll
PY - 2018/8
Y1 - 2018/8
U2 - 10.1111/dom.13321
DO - 10.1111/dom.13321
M3 - Journal article
C2 - 29654643
VL - 20
SP - 1937
EP - 1943
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 8
ER -
